Homrich & Berg trimmed its holdings in Celgene Corporation (NASDAQ:CELG) by 21.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,650 shares of the biopharmaceutical company’s stock after selling 1,287 shares during the period. Homrich & Berg’s holdings in Celgene Corporation were worth $604,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in CELG. State Street Corp lifted its position in shares of Celgene Corporation by 2.3% during the first quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after purchasing an additional 723,844 shares in the last quarter. Jennison Associates LLC lifted its position in shares of Celgene Corporation by 1.2% during the second quarter. Jennison Associates LLC now owns 13,415,734 shares of the biopharmaceutical company’s stock valued at $1,742,301,000 after purchasing an additional 156,864 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Celgene Corporation by 4.9% during the first quarter. Bank of New York Mellon Corp now owns 10,088,473 shares of the biopharmaceutical company’s stock valued at $1,255,309,000 after purchasing an additional 472,067 shares in the last quarter. Pioneer Investment Management Inc. lifted its position in shares of Celgene Corporation by 15.7% during the first quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock valued at $650,911,000 after purchasing an additional 710,584 shares in the last quarter. Finally, Clearbridge Investments LLC lifted its position in shares of Celgene Corporation by 24.1% during the first quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock valued at $572,617,000 after purchasing an additional 892,392 shares in the last quarter. 79.39% of the stock is currently owned by hedge funds and other institutional investors.

In other news, insider Terrie Curran sold 1,727 shares of the stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Gilla Kaplan sold 9,250 shares of the stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the transaction, the director now owns 85,551 shares of the company’s stock, valued at $12,110,599.56. The disclosure for this sale can be found here. Insiders have sold a total of 38,733 shares of company stock valued at $5,259,359 over the last quarter. Corporate insiders own 0.95% of the company’s stock.

WARNING: “Homrich & Berg Sells 1,287 Shares of Celgene Corporation (CELG)” was originally posted by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.watchlistnews.com/homrich-berg-sells-1287-shares-of-celgene-corporation-celg/1674759.html.

A number of research firms recently weighed in on CELG. Oppenheimer Holdings, Inc. reissued an “outperform” rating and set a $175.00 price target (up from $148.00) on shares of Celgene Corporation in a research report on Monday, July 31st. Cantor Fitzgerald set a $160.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Thursday, July 27th. William Blair reissued an “outperform” rating on shares of Celgene Corporation in a research report on Friday, October 20th. BMO Capital Markets restated an “outperform” rating and set a $160.00 price objective (up previously from $152.00) on shares of Celgene Corporation in a report on Friday, July 28th. Finally, Leerink Swann restated a “buy” rating and set a $156.00 price objective on shares of Celgene Corporation in a report on Friday, October 20th. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating, nineteen have issued a buy rating and two have assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $139.64.

Celgene Corporation (NASDAQ:CELG) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The company’s quarterly revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company earned $1.58 EPS.

Celgene Corporation Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.